Advertisement

Biocon Biologics in Covid-19 antibody deal; Byju's mopping up smaller rivals; th

Biocon Biologics, a fully integrated biosimilars company and a subsidiary of Biocon, has won an exclusive license from US-based Adagio Therapeutics to manufacture and commercialise an antibody treatme

By Harichandan Arakali

Forbes India Podcasts

Forbes India Image
How startups are disrupting Indian healthcare
By Naini Thaker
From Auto Components to Cannons: Inside Bharat Forge’s transformation
By Manu Balachandran
From solar to healthcare, how startups are solving for Bharat
By Naini Thaker
Demystifying India's Cabs War
By Naini Thaker
From China's Grip to Made in India: The rare earth magnet dilemma
By Manu Balachandran
View All

From the Bookshelves

K Ganesh has a master key to what makes new-age business models successful
By Divya J Shekhar
Vivek Gambhir and Sunder Ramachandran on building careers in the complex world of work
By Divya J Shekhar
Cricketing legend Mohinder Amarnath on his life, career and being fearless on the field
By Divya J Shekhar , Kathakali Chanda
Former Softbank CFO Alok Sama on the AI bubble, 'founder mode', and Masayoshi Son
By Divya J Shekhar
Ravi Wazir on restaurants in the age of social media and food delivery platforms
By Divya J Shekhar
View All

Forbes India Tech conversations

N Krishnakumar on India's deep tech landscape, the impact of AI, and Mela's second fund
By Harichandan Arakali
Jaicky Kumar and Deepak Mishra on their thermal storage innovation at Voltanova Energy
By Harichandan Arakali
Amit Gupta on Yulu's opportunity to ride the quick commerce wave
By Harichandan Arakali
Founders of Rapid Claims on their conviction in building AI products from India
By Harichandan Arakali
Brijraj Bhuptani on early US growth and lessons from focusing on outcomes first at Spry
By Harichandan Arakali
View All

Money Talks

Gold vs Equity: Which is a better hedge against global recession?
By Neha Bothra
India vs Overseas: Which equity market can deliver better returns? Experts decode the finer nuances
By Neha Bothra
Active vs Passive: Which investment strategy can deliver better long-term returns? Experts weigh in
By Neha Bothra
Invest or avoid: Should HNIs consider pre-IPO investments? Sreeram Reddy Vanga of Kofluence and Arvind Bansal of Avendus Wealth offer their takes
By Neha Bothra
Value vs Growth: Which is a better investment strategy in current times? Rajeev Thakkar of PPFAS MF and Samit Vartak of SageOne Investment Managers debate
By Neha Bothra
View All

One thing today in Tech

IT services: Why the days of sheer people-based delivery are numbered
By Harichandan Arakali
What's driving the modest IT hiring pickup? Hint: not the IT companies
By Harichandan Arakali
Not jugaad, but a scientific approach to using AR and Gen AI in schools
By Harichandan Arakali
What Zoho is doing in AI? Here's what you should know
By Harichandan Arakali
The high cost of AI development and what that means for many countries
By Harichandan Arakali
View All
Advertisement
Advertisement

Latest News